<DOC>
	<DOCNO>NCT01490255</DOCNO>
	<brief_summary>No previous study assess potential ranolazine interfere level platelet reactivity patient coronary artery disease treat dual antiplatelet therapy . Aim study compare pharmacodynamic effect maintenance dose ranolazine versus amlodipine platelet reactivity patient coronary artery disease treat dual antiplatelet therapy .</brief_summary>
	<brief_title>Pharmacodynamic Effects Ranolazine Versus Amlodipine Platelet Reactivity</brief_title>
	<detailed_description>Patients coronary artery disease ( CAD ) often treat dual antiplatelet therapy ( DAT ) , include aspirin clopidogrel , prevent recurrent atherothrombotic event . Levels platelet reactivity patient DAT influence concomitant treatment medication inhibit CYP3A4 system involve activation clopidogrel , calcium channel blocker , potentially interfere clinical benefit . Importantly , calcium channel blocker , amlodipine , commonly use relief ischemic symptom patient CAD . Ranolazine novel antianginal drug reduces intracellular sodium calcium accumulation constitute pharmacologic alternative calcium channel blockade . However , previous study assess potential ranolazine interfere level platelet reactivity CAD patient DAT . The primary objective study compare pharmacodynamic effect maintenance dose ranolazine versus amlodipine platelet reactivity patient CAD DAT .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Ranolazine</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Angiographicallyproven coronary artery disease Class I indication dual antiplatelet therapy recent ( &lt; 12 month ) percutaneous coronary intervention and/or recent acute coronary syndrome ( &lt; 12 month ) Stable clinical condition Able understand willing sign inform consent form Use drug interfere CYP activity proton pump inhibitor Women child bear potential patient must demonstrate negative pregnancy test perform within 24 hour</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>platelet reactivity</keyword>
	<keyword>aspirin</keyword>
	<keyword>clopidogrel</keyword>
</DOC>